Marea Therapeutics
CompanyUnited States
Marea Therapeutics develops one asset, in phase 2 (MAR002 in acromegaly). Mostly other acting on Insulin/IGF-1 signalling and IGF1; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 1
- Signal
Pipeline
1Suppression of IGF-1
Phase 2, Other, Insulin/IGF-1 signalling, IGF1, acromegaly
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Signals1
- Similar companies6
Papers
ENDO 2025 abstract, 23 Oct 2025